Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Orthopediatrics (KIDS) EBIT (2016 - 2025)

Historic EBIT for Orthopediatrics (KIDS) over the last 10 years, with Q3 2025 value amounting to -$9.4 million.

  • Orthopediatrics' EBIT fell 6938.56% to -$9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.1 million, marking a year-over-year decrease of 5547.71%. This contributed to the annual value of -$35.0 million for FY2024, which is 3087.36% down from last year.
  • Orthopediatrics' EBIT amounted to -$9.4 million in Q3 2025, which was down 6938.56% from -$10.7 million recorded in Q2 2025.
  • Orthopediatrics' 5-year EBIT high stood at -$2.8 million for Q2 2021, and its period low was -$14.1 million during Q4 2024.
  • In the last 5 years, Orthopediatrics' EBIT had a median value of -$6.4 million in 2022 and averaged -$7.2 million.
  • Its EBIT has fluctuated over the past 5 years, first surged by 5944.14% in 2021, then tumbled by 9102.63% in 2022.
  • Over the past 5 years, Orthopediatrics' EBIT (Quarter) stood at -$5.6 million in 2021, then crashed by 49.42% to -$8.3 million in 2022, then grew by 2.92% to -$8.1 million in 2023, then plummeted by 74.25% to -$14.1 million in 2024, then surged by 32.92% to -$9.4 million in 2025.
  • Its EBIT stands at -$9.4 million for Q3 2025, versus -$10.7 million for Q2 2025 and -$11.0 million for Q1 2025.